Order Article Reprints

Huen A, Haverkos BM, Zain J, Radhakrishnan R, Lechowicz MJ, Devata S, Korman NJ, Pinter-Brown L, Oki Y, Barde PJ, et al. Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma. Cancers. 2020; 12(8):2293. https://doi.org/10.3390/cancers12082293

Huen, Auris, Bradley M. Haverkos, Jasmine Zain, Ramchandren Radhakrishnan, Mary Jo Lechowicz, Sumana Devata, Neil J. Korman, Lauren Pinter-Brown, Yasuhiro Oki, Prajak J. Barde, and et al. 2020. "Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma" Cancers 12, no. 8: 2293. https://doi.org/10.3390/cancers12082293

Huen, A., Haverkos, B. M., Zain, J., Radhakrishnan, R., Lechowicz, M. J., Devata, S., Korman, N. J., Pinter-Brown, L., Oki, Y., Barde, P. J., Nair, A., Routhu, K. V., Viswanadha, S., Vakkalanka, S., & Iyer, S. P. (2020). Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma. Cancers, 12(8), 2293. https://doi.org/10.3390/cancers12082293